Insmed reported $153.54M in Operating Expenses for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Operating Expenses Change
DBV Technologies DBVT:US 25.35M 6.04M
Acelrx Pharmaceuticals ACRX:US $ 14.14M 4.71M
Alimera Sciences ALIM:US $ 16.58M 533K
Biomarin Pharmaceutical BMRN:US $ 494.65M 112.61M
Cytokinetics CYTK:US $ 99.84M 18.14M
Dynavax Technologies DVAX:US $ 128.24M 45.01M
Gilead Sciences GILD:US $ 4231M 2162M
Heron Therapeutics HRTX:US $ 77.13M 9.25M
Insmed INSM:US $ 153.54M 10.6M
Mirati Therapeutics MRTX:US $ 182.57M 2.36M
Novartis NVS:US 10.86B 895M
Ophthotech OPHT:US $ 49.75M 15.08M
Regeneron Pharmaceuticals REGN:US $ 1747.3M 40.7M
Sarepta Therapeutics SRPT:US $ 444.62M 146.91M
Seattle Genetics SGEN:US $ 630.61M 71.1M
Ultragenyx Pharmaceutical RARE:US $ 230.94M 14.37M
Vertex Pharmaceuticals VRTX:US $ 1089.9M 33.3M